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ABSTRACT
CONTEXT AND OBJECTIVE: Counting and separating hematopoietic stem cells from different sources has importance for research and clinical assays. 
Our aims here were to characterize and quantify hematopoietic cell populations in marrow donors and to evaluate CD34 expression and relate this to 
engraftment. 
DESIGN AND SETTING: Cross-sectional study on hematopoietic stem cell assays, using flow cytometry on donor bone marrow samples, for allogenic 
transplantation patients at two hospitals in São Paulo.
METHODS: Immunophenotyping of marrow cells was performed in accordance with positive findings of CD34FITC, CD117PE, CD38PE, CD7FITC, CD33PE, 
CD10FITC, CD19PE, CD14FITC, CD13PE, CD11cPE, CD15FITIC, CD22PE, CD61FITC and CD56PE monoclonal antibodies in CD45PerCP+ cells, searching 
for differentiation and maturation regions. CD34+ sorting cells were analyzed for CD38 and CD117. Rh-123 retention was done before and after sorting. 
Antigen expression and CD34+ cells were correlated with engraftment.
RESULTS: In region R1, 0.1% to 2.8% of cells were CD34+/CD45+ and 1.1%, CD34+/CD45-. The main coexpressions of CD45+ cells were CD38, 
CD22, CD19 and CD56 in R2 and CD33, CD11c, CD14, CD15 and CD61 in R3 and R4. After sorting, 2.2x106 CD34+ cells were equivalent to 4.9% of 
total cells. Coexpression of CD34+/CD38+ and CD34+/CD117+ occurred in 94.9% and 82% of events, respectively. There was a positive relationship 
between CD34+ cells and engraftment. More than 80% of marrow cells expressed high Rh-123. CD34+ cell sorting showed that cells in regions of more 
differentiated lineages retained Rh-123 more intensively than in primitive lineage regions. 
CONCLUSION: We advocate that true stem cells are CD34+/CD45-/CD38-/low-Rh-123 accumulations.
RESUMO
CONTEXTO E OBJETIVO: A contagem e separação de células-tronco hematopoéticas de diferentes fontes tem importância para ensaios clínicos e pesquisa 
basica. Nosso objetivo foi caracterizar e quantificar as populacões de células hematopoéticas, bem como avaliar a expressão do antígeno CD34 em 
populações mais primitivas e correlacioná-las com a enxertia nos doadores de medula óssea para transplante alogênico.
TIPO DE ESTUDO E LOCAL: Estudo transversal no qual a diferenciação e a seleção de células-tronco hematopoéticas foram realizadas em amostras de 
medula óssea de doadores de pacientes submetidos a transplante alogênico nos Hospitais São Paulo e Santa Marcelina, São Paulo, Brasil.
MÉTODOS: Imunofenotipagem de células mononucleares de medula óssea foi feita na população de células CD45PerCP+ com os seguintes anticorpos: 
CD34FITC, CD117PE, CD38PE, CD7FITC, CD33PE, CD10FITC, CD19PE, CD14FITC, CD13PE, CD11cPE, CD15FITC, CD22PE, CD61FITC e CD56PE. Após 
a definição de regiões de células positivas ao CD34, estas células foram selecionadas e analisadas para a co-expressão do CD38 e CD117. Células 
mononucleares totais de medula óssea e aquelas obtidas após a seleção foram testadas para a retenção de Rh-123. O teste de Friedman e o coeficiente 
de Sperman foram utilizados para comparar as expressões e correlacionar a contagem de células CD34+ com a enxertia.
RESULTADOS: Na região R1, 0,1% a 2,8% das células foram CD34+/CD45+, porém apenas 1,1% das células foram CD34+/CD45-. As principais co-
expressões de células CD45+ foram CD38, CD22, CD19 e CD56 na região R2 e CD33, CD11c, CD14, CD15 e CD61 nas regiões R3 e R4. Após a seleção, 
a mediana de 2,2x106 células CD34+ foi equivalente a 4,9% do total mediano de células da medula óssea. Co-expressões de células CD34+/CD38+ e 
CD34+/CD117+ ocorreram em 94,95 e 82%, respectivamente. Houve relação positiva entre o número de células CD34+ infundidas e o dia da enxertia. 
Observamos que mais de 80% das células mononucleares de medula óssea retêm intensamente a Rh-123. Após a seleção, células localizadas em 
regiões de maior diferenciação, regiões R3 e R4, acumulam mais fortemente a Rh-123 do que células mais primitivas da região R1.
CONCLUSÃO: Postulamos que a célula tronco hematopoética mais primitiva expressa o seguinte fenótipo: CD34+/CD45-/CD38-/Rh-123 de baixa retenção.
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INTRODUCTION
Quantification of CD34+ cells has an essential role in hematopoi-
etic stem cell transplantation, whether autologous or allogenic, since the 
engraftment itself results from proliferation of the true hematopoietic 
stem cells. On the other hand, the progenitor cells expressing CD34 on 
the surface, which are already committed to some level of differentia-
tion, sustain hematopoiesis only temporarily.1,2
The CD34 antigen is highly expressed in pluripotent cells, and its 
expression gradually reduces as the level of maturation of hematopoiet-
ic cell lineages increases, to the point of becoming completely absent in 
fully mature cells.3-5 By immunophenotyping CD34+ cells, it becomes 
evident that more than 95% of these cells are already committed to a 
particular lineage, since they also express lymphoid or myeloid-specific 
antigens. Prominent among these antigens is CD38, which is positively 
expressed in more than 90% of CD34+ cells. With regard to CD38 ex-
pression intensity, hematopoietic progenitors are classified as early (low 
CD38 expression) or differentiated progenitors (higher CD38 expres-
sion). A human B-cell/myeloid common progenitor expressing CD34+/
CD38low/CD19+/CXCR4- has been identified.6  
Other molecules may be useful in identifying marrow progenitors, 
especially CD117 (c-kit). This proto-oncogene codes for a protein recep-
tor present in CD34+ cells. CD117 ligand (c-kit ligand), or stem cell fac-
tor, is produced by stromal cells. Achieving interaction between CD117 
and its ligand is one of the necessary steps in the maturation process for 
marrow cells, together with interactions with other growth factors.5,7
B-lineage immature cells characteristically express CD34, HLA-DR 
and high-intensity CD10 (also known as CALLA), while B cells with 
greater differentiation express CD45, CD22, CD19, TdT and low-in-
tensity CD10.6,8 Myeloid progenitors positively express CD34, CD33 
and CD13 in more immature cells; and CD11b, CD11c and CD15 are 
expressed mainly in mature granulocytic cells. Monocytic cells express 
CD14, and CD61 is specific to cells committed to megakaryopoiesis9,10 
The thrombopoietin receptor is now an important marker for sepa-
rating granulocyte/monocyte from megakaryocyte/erythroid precur-
sors, because of difficulty in distinguishing CD19-/CD34+/IL-3Rαlow-/
CD45RA-/TpoR- from CD19-/CD34+ /IL-3Rαlow+/CD45RA-/
TpoR+ based only on IL-Rαlow expression.9,10 Rhodamine-123 (Rh-
123) is a useful tool for identifying hematopoietic cells that are more 
primitive. This substance accumulates in metabolically active cells. In 
hematopoietic cells, the number of mitochondria is small, reflecting 
their low metabolic rate, and this leads to low accumulation of Rh-123. 
On the other hand, cells with greater differentiation show a higher met-
abolic rate and accumulate more Rh-123.11
OBJECTIVE
In this report, our objectives were the following: to use flow cytom-
etry to characterize and quantify different populations of hematopoietic 
cells in healthy marrow donors; to evaluate CD34 expression and relate 
this to engraftment day; and to evaluate the pattern of CD34 expression 
in relation to Rh-123 retention and CD38 and CD117 coexpression in 
CD34+/CD45- cells.
METHODS
Eleven marrow samples (10 ml) from healthy donors that were ob-
tained for allogenic stem cell transplantation were analyzed. Among the 
marrow recipients, seven were diagnosed with chronic myeloid leuke-
mia, one with multiple myeloma, one with severe aplastic anemia, one 
with lymphoblastic T-cell non-Hodgkin’s lymphoma and one with Phil-
adelphia-positive acute lymphoblastic leukemia.
Mononuclear cells were separated by means of Ficoll-Hypaque gra-
dient. Buffy coats were washed and resuspended in phosphate-buffered 
saline (PBS). After performing cell counts and evaluating cell viability, 
the cell samples were cryopreserved using 60% Roswell Park Memorial 
Institute (RPMI) medium, 20% fetal calf serum and 20% dimethyl sul-
foxide solution (one part of cell suspension to one part of cryopreserved 
solution). Freezing was performed gradually until the temperature de-
clined to 8 °C, -20 °C, -80 °C and -196 °C. Defrosting was performed 
using double boiling, followed by rinsing with RPMI. Finally, Buffy 
coats were resuspended in PBS.
For immunophenotyping, 50 µl of PBS-azide (pH 7.4) and the 
following fluorochrome-conjugated monoclonal antibodies were add-
ed to the PBS-marrow suspension: CD34FITC, CD117PE, CD38PE, 
CD7FITC, CD33PE, CD10FITC, CD10PE, CD14FITC, CD13PE, 
CD11cPE, CD15FITIC and CD56PE. These were diluted in accor-
dance with the manufacturer’s specifications and their associations with 
CD45PerCP were tested. After a short incubation time, the cells were 
rinsed with 2 ml of PBS-azide and finally resuspended in 1% paraform-
aldehyde until the time of data acquisition. 
The data acquisition and analysis were performed using Becton-
Dickinson FACScalibur and CellQuest software. We established that 
the minimum number of events to be acquired prior to analysis needed 
to be 25,000. The positive control was CD45 and the negative control 
was gamma-1 gamma-1. 
After defining the region of CD34 positivity, CD34-positive cells 
were sorted among ten of eleven samples, for further analysis regarding 
the expression of CD38 and CD117.
In the next step, the marrow mononuclear cell suspension (106 cells/
ml) was incubated for 20 minutes with a solution of PBS, fetal calf se-
rum, water and Rh-123 (1 µg/ml). The cells were then washed with 
RPMI twice, resuspended in PBS/0.25% fetal calf serum and kept on 
ice, protected from light, until data acquisition. The analysis of Rh-123 
accumulation, compared with CD34 positivity, was performed using 
Paint-a-gate (BD) software.
The Friedman test and Spearman coefficient were used to compare 
the median percentages of each specific CD expression, and to correlate 
the absolute number of CD34+ cells with the day of engraftment.
RESULTS
Four regions were defined, according to the positivity pattern of 
the antigens studied (R1, R2, R3 and R4) (Figure 1). Considering that 
CD45 is almost completely absent in more primitive marrow cells and 
that its expression differs among lineage-committed progenitors (lym-
phoid, myeloid, megakaryocytic and natural killer cells), we chose to an-
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alyze its expression in relation to specific lineage determinants, labeled 
with different fluorochromes. We started by characterizing the CD34 
and then identified the cells with greater differentiation that were al-
ready committed to any of the above mentioned cell lines, to express 
lineage-specific antigens.
In region R1, 0.1% to 2.8% of the cells were positive for both 
CD34 and CD45. It is also noteworthy that 1.1% of the cells were 
CD34+/CD45- (Figure 2). In region R2, the cell immunophenotypes 
that were most frequently positive (> 30%) included CD34+/CD45+, 
CD117+/CD45+, CD13+/CD45+, CD33+/CD45+, CD22+/CD45+ 
and CD38+/CD45+ (Figures 1 and 3).
In region R3, the cell immunophenotypes that were most fre-
quently positive (> 30%) included CD117+/CD45+, CD13+/CD45+, 
CD14+/CD45+, CD33+/CD45+, CD38+/CD45+, CD11c+/CD45+ 
and CD15+/CD45+ (Figures 1 and 3).
In region R4, the most frequent phenotypes were CD117+/CD45+, 
CD13+/CD45+, CD14+/CD45+, CD33+/CD45+, CD38+/CD45+, 
CD61+/CD45+, CD11c+/CD45+, CD15+/CD45+ (> 39%) and 
CD61+/CD45+ (38%) (Figures 1 and 3).
After sorting the CD34+ cells, we found a median number of 2.2 
x 106 cells, which was equivalent to 4.9% of the total number of cells. 
With the exception of the patient with severe aplastic anemia, we were 
able to demonstrate that the higher the number of CD34+ cells was, 
the earlier the engraftment took place. Our analyses revealed a positive 
relationship between the number of infused CD34-positive cells and 
the engraftment day (Table 1). After sorting the CD34 +/CD45+ cells, 
the proportion of these that coexpressed CD38 was high, ranging from 
86.5 to 98.8%, with a median of 94.9% (Table 2). The same cells coex-
pressed CD117, ranging from 32% to 98.8%, with a median of 82.5%, 
as shown in Table 3. From analyzing the cells that captured Rh-123 in 
relation to the total number of mononuclear cells, it was evident that 
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Figure 1. Immunophenotypic characterization of marrow stem cells. 
Distribution of marrow cells according to CD45 expression and complexity. 
Four regions can be identified (R1-R4). 
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Figure 3. Immunophenotypic characterization of marrow stem cells. CD45+ cells are distributed predominantly in regions R2, R3 and R4 and they share 
markers of myeloid and lymphoid lineages. 
8
6
4
2
R1 R2 R3 R4
Region
* *
n=11
0
%
 C
D3
4 
+ 
/ 
CD
45
-
Figure 2. Immunophenotypic characterization of marrow stem cells. 
Hematopoietic stem cells (CD34+/CD45-) are significantly more 
concentrated in region 1. Samples from 11 patients were analyzed. 
*statistically significant
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more than 80% of the mononuclear cells expressed high levels of Rh-
123 accumulation. By evaluating the CD34+ cells alone, we observed 
that cells located in the regions with greater differentiation retained Rh-
123 more intensively, while the more primitive CD34-positive cells (lo-
cated in R1) accumulated less Rh-123 (Figure 4).
DISCUSSION
Better understanding of hematopoietic stem cell physiology and 
subpopulation distribution is still required. Flow cytometry has proved 
to be a useful tool for this, since it is fast and it identifies and quantifies 
these subpopulations, in their various stages of maturation.10
This study was based on characterization of the hematopoietic stem 
cell subpopulations in regions R1, R2, R3 and R4, which were already 
known to include cells with positive expression of the antigens listed 
above.8 Our results were similar to what had previously described, espe-
cially with regard of simultaneous expression of myeloid and lymphoid 
antigens in region R2. In this region, the cells were CD19+/CD22+/
CD13+/CD33+, thus indicating very little degree of differentiation. 
This characteristic has been defined as “antigenic infidelity”.2,5,8,12 
In the subsequent differentiation steps, we were able to define re-
gions of progressive lineage commitment, with cells expressing antigens 
that were more specific to definite cell lineages, as shown in regions R3 
and R4 (Figures 1 and 3).
Region R1 included cells that were CD45-negative. These had 
a minimum level of differentiation, and most of them proved to be 
CD34-positive (Figure 2). The expression of CD45 increased progres-
sively, in parallel with the cell maturation, as seen in regions R3 and R4 
(Figure 3).
Using a specific combination of anti-B lymphocyte antibodies, we 
were able to locate B-cells in the regions according to their degree of 
maturation. Most B-cell precursors remained in region R2, thus coin-
ciding with the region that included most of the CD34-positive cells 
(Figure 3). The concomitant expression of myeloid antigens in this re-
gion supports the idea that these cells still do not have much differentia-
tion and do not possess lineage-specific antigens alone. 
The simultaneous expression of CD45, CD45RA and CD38 in 
lymphoid B-cells is a peculiar pattern. Both CD45 and CD45RA are 
Patients
Total CD34+  
cells harvested
% CD34+ cells
Engraftment day 
(D+)
1. BJTA 3.1 x 109 3.9% 18
2. JLPS 16 x 109 13.8% 15
3. MSCP 2.2 x 109 4.0% *
4. NMSP 4.4 x 109 10.9% 19
5. MLG 2.0 x 109 4.9% 23
6. ESK 2.0 x 109 2.1% 22
7. RRST 5.9 x 109 6.7% 18
8. EP 2.4 x 109 7.5% 16
9. JFRJ 7.0 x 109 2.7% 23
10. LAS 8.0 x 109 2.0% 17
11. NOS 1.1 x 109 6.6% 25
Median 2.0 x 109 4.9% 18
*death before engraftment.
Table 1. Correlation between CD34+ cells and engraftment
Patients After sorting of CD34+/CD45/CD38+ cells
1. BJTA 87.6
2. JLPS 98.8
3. MSCP 95.3
4. NMSP 95.2
5. MLG 91.4
6. ESK 95.6
7. RRST 98.8
8. EP 90.9
9. JFRJ 94.6
11. NOS 86.5
Median 94.9
Table 2. Expression of CD34/CD38 after sorting of CD34+/CD45- cells
Patients After sorting of CD34+/CD45/CD117+ cells
1. BJTA 32.0%
2. JLPS 98.8%
3. MSCP 94.8%
4. NMSP 75.1%
5. MLG 35.2%
6. ESK 89.8%
7. RRST 95.6%
8. EP 48.6%
9. JFRJ 97.1%
11. NOS 44.0%
Median 82.5%
Table 3. Expression of CD34/CD117 after sorting of CD34+/CD45- cells
Figure 4. Distribution and percentage of marrow cells according to 
expression of CD34 and rhodamine uptake. R1: CD34+/low-intensity 
rhodamine; R2: CD34+/high-intensity rhodamine; R3: CD34-/rhodamine-
negative. 
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increasingly expressed when the CD10 expression declines. On the oth-
er hand, CD38 follows CD10 expression, until the cells become mature 
enough and are released into the blood stream. CD38 will be again ex-
pressed when these lymphocytes become activated.6,13-15 
With regard to lymphocyte differentiation, CD10 expression is ini-
tially regulated by the presence of CD34, as well as CD3 expression. 
CD10 is little expressed until the immunoglobulin heavy-chain (IgH) 
genes have been rearranged and the IgH protein reaches the membrane. 
CD3 (T-cell receptor) is only expressed after the genes coding for this 
protein have been rearranged. These characteristics constitute evidence 
for defining the immunophenotype of the less differentiated B-cells as 
CD34+/CD19+/CD10+ (low intensity), in the presence of rearranged 
IgH protein. The region with the highest concentration of B-cell pre-
cursors, according to the surface antigen pattern, was R2. In this region, 
we found that 30% of the cells were CD22+ and 18% were CD19+, i.e. 
proportions similar to what was found by Loken et al.16 and Pontvert-
Delucq et al.12 At present, identification of a common B-cell/myeloid 
progenitor by means of absence of CXCR4 in the early CD34+/CD19+ 
population emphasizes the idea of maturation infidelity among the cells 
from this region.6 However, CD34+/CD19-/CD45RA- with low or ab-
sent IL-3Rα and TpoR may distinguish common myeloid/monocyte 
from megakaryocyte/erythroid precursors.9
Chabannon et al.17 demonstrated that small populations of CD34+/
CD7+ cells may correspond to progenitor cells that still lack lineage 
commitment and can differentiate to granulocytes, when subjected 
to long-term marrow culturing. Miller et al.18 postulated that these 
CD34+/CD7+ cells constitute an intermediary stage in natural kill-
er (NK) cell differentiation. In our samples, the median proportion of 
CD7/CD45 in region R1 represented only 0.5% of the total number of 
cells in this region (Figure 3).
In myelopoiesis, 41% of the CD34-positive cells also expressed 
CD33 and CD45 in R2. This percentage increased to 58% in R3 and 
68% in R4, with median values that were statistically different from the 
median R1 value (Figure 3). For the same regions, Syrjälä et al.8 found 
27% (R2), 73% (R3) and 94% (R4).
Myeloid cells with greater differentiation expressed CD13 and 
CD45 in a similar way to what was observed by Inaba et al.19 We found 
proportions of CD13+/CD45+ of 53% in R2, 54% in R3 and 54% in 
R4 (Figure 3).
Immature granulocytic precursors show immunophenotypes akin 
to monocytes and NK cells. CD11c and CD11b are helpful in identify-
ing granulocytic cells of greater maturity, since they are not expressed in 
the more immature ones. Adding CD15 to the panel also provides more 
information for characterizing granulocytes with greater differentiation, 
especially promyelocytes and myeloblasts.14,20 Neutrophils can be dis-
tinguished from eosinophils by the positive expression of CD16 in the 
former and negative expression in the latter.
We evaluated the presence of granulocytic committed cells by an-
alyzing the expression of CD11c, CD15 and CD14 (monocytes). 
CD11c+/CD45+/CD34+ cells amounted to 37% in R3 and 49% in 
R4. R1 and R2 showed no significant expression of these antigens, and 
this was also observed by Syrjälä et al.8 and Terstappen et al.13 Monocyt-
ic cells (CD14+/CD45+) amounted to 34% of the cells in R3 and 55% 
in R4. This pattern of expression was significantly different from the ex-
pression in regions 1 and 2. Syrjälä et al.8 found proportions of CD14+/
CD45+ cells of 3% in R3 and 30% in R4. Our results may be explained 
by contamination of marrow samples with cells of greater maturity from 
the blood stream, at the time of marrow harvesting for donation.
NK cells express CD56 and are negative for CD3. It has been hy-
pothesized that the NK progenitor is related to the most primitive 
CD34-positive cells. Miller et al.18 obtained mature NK cells from long-
term marrow culturing. Our data show that NK cells were present in 
areas where CD34 was also expressed (values between 8% and 13% in 
regions 2, 3 and 4, Figure 3). We were unable to compare these data 
with other groups, since no such studies have been reported, as far as we 
know. However, a common origin for NK cells and lymphoid and my-
eloid precursors has been now advocated.21-23 
Exposure of CD34-/CD133-/CD7-/CD45dim/lin- hematopoietic 
stem cells  from  human cord blood to stem cell factor in long-term 
marrow cultures has been associated with the following: 1) concordant 
expression of the antigens CD34 and CD133; 2) generation of colo-
ny-forming unit (CFU) granulocyte-macrophages, burst-forming unit 
erythroids and megakaryocytic aggregates; 3) significant extended long-
term marrow culture-initiating cell activity; and 4) upregulation of mes-
senger ribonucleic acid (mRNA) signals for myeloperoxidase. At vari-
ance with CD34+/lin- cells, CD34-/CD133-/CD7-/CD45dim/lin- he-
matopoietic stem cells maintained with IL-15 but not with IL-2 or IL-7 
have been found to proliferate and differentiate into a homogeneous 
population of CD7+/CD45(bright)/CD25+/CD44+ lymphoid pro-
genitors with high expression of the T-cell-associated transcription fac-
tor GATA-3. Despite harboring non-clonally rearranged TCRγ genes, 
IL-15-primed CD34-/CD133-/CD7-/CD45dim/lin- hematopoietic 
stem cells have been found not to achieve full maturation, as mani-
fested in their CD3-/TCRαβ-/γδ- phenotype. Conversely, cultures on 
stromal cells supplemented with IL-15 have been associated with acqui-
sition of NK cells. Collectively, CD34-/CD133-/CD7-/CD45dim/lin- 
hematopoietic stem cells from human umbilical cord blood have been 
found to display exquisite sensitivity to IL-15 and differentiation into 
lymphoid/NK cells.21
Long-term marrow culturing of the CD56-/CD34- myeloid-like ad-
herent cell fraction (ACF) from umbilical cord blood, characterized by 
CD14+ expression and myeloid markers set up with flt3 ligand (FL) and 
IL-15, have been found to gradually express CD56, reaching high lev-
els of approximately 90% by day 15. FL plus IL15-driven ACF/CD56+ 
cells have been found to progressively express an NK program, thereby 
lysing both NK and LAK-sensitive tumor cells and producing high lev-
els of interferon-gamma (IFN-γ), granulocyte/macrophage-colony stim-
ulating factor (GM-CSF), tumor necrosis factor alpha (TNF-α) and IL-
10, upon stimulation with IL-12 and IL-18. Similar results have been 
obtained with highly purified CD14+ cells from umbilical cord blood, 
cultured with FL and IL-15. In contrast, umbilical cord blood/CD34+ 
cells cultured under the same conditions have shown delayed expres-
sion of CD56, with different behavior in that they exhibited NK but 
not LAK cytotoxicity and produced significantly fewer cytokines. Ki-
netic studies on the phenotype of umbilical cord blood/ACF or umbili-
cal cord blood/CD14+ cells has shown a rapid decrease in CD14 expres-
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sion after day 5, reaching levels of zero by day 20. Approximately 60% of 
the CD56+ derived from umbilical cord blood/ACF or umbilical cord 
blood/CD14+ cells has been found to coexpress CD14 by day 5. 
Taken together, these data support the hypothesis that CD14+ my-
eloid-like cells have a role in umbilical cord blood as a novel progeni-
tor for lymphoid NK cells.22 Furthermore, early-sorted CD34+/CD56+ 
stem cells in peripheral blood maintained in long-term marrow cultures 
with IL-2 and stem cell factor have been found to differentiate into 
two CD56 cells populations: one CD56bright/CD33- population with 
large granular lymphocyte morphology and cytoplasmatic granzyme-A 
but lacking a killer inhibitory receptor (thus suggesting that they are 
immature NK cells); and another CD56dim/CD33+ population with 
macrophage morphology that proliferates and produces a variety of cy-
tokines upon lipopolysaccharide stimulation, including IL-18, IL-6, 
monocyte chemoattractant protein and macrophage-derived chemok-
ines, but not IFN-γ.23 Thus, true differentiation of CD34 cells to NK 
cells remains to be determined. 
Megakaryocytic precursors have shown CD34 and positive HLA-
DR and have exhibited platelet-specific antigens as the maturation proc-
ess comes to completion (CD41, CD42, CD61, CD36 and CD62).24 
We observed CD61+/CD45+ cells in R3 (26%) and R4 (38%). Like-
wise, there are no comparable reports regarding megakaryopoiesis im-
munophenotypic distribution, to the best of our knowledge. A com-
mon CD19-/CD34+/IL-3Rαlo+/CD45RA-/TpoR+ megakaryocyte-
erythrocyte precursor has been recognized.9 
Some authors advocated15,22,23 that true stem cells are CD34+/
CD45-/CD38-. This phenotype was found in region R1 in our study 
(Figure 2). Since only a small proportion of cells express CD34, in rela-
tion to the whole volume of cells, with consequent difficulty in isolat-
ing them and possible contamination with other cell populations, we 
chose to perform cell sorting, thereby achieving a considerable degree 
of specificity.
In order to demonstrate the most primitive hematopoietic stem cell, 
we coupled the quest for CD34-positive cells with an investigation into 
which of these cells were CD117 and CD38-positive. These very primi-
tive cells are known to be CD34+/CD38-, but the latter antigen be-
comes evident in progenitors with greater differentiation (90% positiv-
ity) until its disappearance from fully differentiated cells.13 
Escribano et al.7 reported that more than 50% of CD34+ cells also 
expressed CD117, including progenitors committed to erythroid, gran-
ulocytic and monocytic lineages, along with small populations of NK 
and T-cell precursors. Sperling et al.25 and Ashman et al.26 stated that 
70% of CD34-positive marrow cells were also CD117-positive. Recent-
ly, CD34+/CD38- cells were reported to be particularly distinguished 
by: (1) a capability for secondary hematopoietic reconstitution of hu-
man cord blood;27 (2) a capability, among CD34+/CD38- cells from 
umbilical cord blood, to divide and proliferate in vitro for at least six 
months without showing any increase in apoptosis or any numerical or 
structural chromosomal abnormalities;28 and (3) a capability to present 
genes from megakaryopoiesis, in cells obtained from CD34+/CD38low 
that were cultured in serum-deprived medium supplemented with IL-3, 
IL-6, stem cell factor and thrombopoietin.29 Thus, CD34+/CD38- cells 
come very close to being true hematopoietic stem cells.
CD117 expression occurs in myeloid and T-lymphoid lineages, and 
this molecule determines two differently sized groups of CD34-positive 
cells, with regard to higher or lower intensity of expression. CD34+/
CD117+ cells with low expression form a small population that is be-
lieved to reconstitute hematopoiesis after marrow ablation.7,14,20 
Among the ten samples analyzed, we found a median CD34 expres-
sion of 4.9%, which was similar to published data. CD34/CD38 coex-
pression occurred in 94.9% of the events and CD34/CD117 coexpres-
sion in 82% (Tables 2 and 3).
Regarding CD34/CD117 coexpression, it was shown that CD117 
was absent from the CD34-positive cells located in R1. There have been 
reports stating that true hematopoietic stem cells do not express CD117 
on the membrane, but that CD117 m-RNA can be detected.7,25,26 
Rh-123 is one of the substrates of P-glycoprotein (Pgp), and the 
presence of active Pgp can be shown by the efflux of Rh-123. Rh-123 
can also be used to measure the mitochondrial transmembrane poten-
tial (energy state) of a cell. It was reasoned that the quantity of he-
matopoietic progenitors selected using a combination of Rh-123 efflux 
and phenotypic markers might be superior to the quantity selected by 
using phenotypic markers alone.11 High Rh-123 retention was seen in 
80% of the mononuclear cells in the marrow cell population, and this 
population was related to the more mature cells. After separation of the 
CD34-positive cells, 95.3% of the CD34-negative cells were associat-
ed with high Rh-123 retention. Moreover, out of the 4.7% of all of the 
CD34 cells that were positive, 3.4% presented high Rh-123 retention 
and 1.3% presented low retention. It is remarkable that the total quan-
tity of CD34-positive cells obtained by sorting analysis was the same 
as the sum of CD34-positive cells with high and low Rh-123 retention 
cells (Figure 4). This finding leads to the conclusion that the low Rh-
123/CD34-positive cells were close in quantity to the CD34-positive 
and CD45-negative cells found in region R1, and they might repre-
sent the most primitive hematopoietic cell population. Transplantation 
of cell populations with high and low Rh-123 retention into irradiated 
mouse recipients revealed that the robust megakaryocyte differentiation 
was from low Rh-123 retention cells. Thus, in an animal model, the dif-
ferentiation capability of these early CD34 hematopoietic progenitor 
cells was confirmed.15 
We highlight that identification of CD34+/CD38- cells associated 
with low Rh-123 retention is currently of high interest in general medi-
cine, in relation to repairing damage in cardiac, orthopedic and several 
other diseases. Today, hematopoietic stem cells have become a new focus 
for treating degenerative diseases.30 We foresee that our technique for sepa-
rating hematopoietic stem cells will form a useful strategy for experimental 
and therapeutic applications requiring human stem cells in large quantity. 
CONCLUSION
CD34+/CD38- and CD34+/CD117- immunophenotypes were 
found in region R1, subsets of myeloid and lymphoid precursors were 
seen in region R2 and defined lineage maturations cells were seen in re-
gions R3 and R4.
The average proportion of CD34+ cells was 4.9% and there was a 
correlation between the total number of these cells and engraftment day. 
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High Rh-123 retention was found in 80% of mononuclear marrow 
cells. This population was related to more mature cells. Overall, in the 
CD34+ cells, the mean low Rh-123 retention rate was 1.3% and the 
mean high Rh-123 retention rate was 3.4%. The low Rh-123 retention 
rate in region R1 was close to the proportion of CD34+ cells found in 
that region, and this may represent the most primitive stem cell popu-
lation.
The total number of CD34+ cells obtained by sorting analysis was 
close to the sum of CD34+ cells with high and low Rh-123 retention.
We advocate that true stem cells are CD34+/CD45-/CD38-/low-
Rh-123 accumulations.
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